For screening of tumors with a known low frequency of NTRK fusions where NGS is not routinely performed (e.g., colon cancer), Penault‐Llorca and colleagues recommend pan‐TRK immunohistochemistry (IHC) and, if positive, NGS.22 This evidence concerns the gene NTRK1 and malignant colon neoplasm.